Award will fund retrovirus-associated cancer research.

A team of researchers from Ohio State University’s Comprehensive Cancer Center (OSUCCC) and the university’s College of Veterinary Medicine received a $10.9 million, five-year grant from the NCI to further their studies of retrovirus-associated cancer.

This backing follows a previous five-year, $8.9 million NCI award received in 2003 for studies investigating how some retroviruses cause white blood cells to proliferate leading to cancer.

The study comprises five interactive projects to define critical biological events that control the alteration of lymphocytes. “These findings will help us further discover therapeutic targets against retroviral-induced lymphoma and its lethal side effects syndromes such as hypercalcemia,” says principal investigator Michael Lairmore, Ph.D., professor and chair of the department of veterinary biosciences and associate director for basic research at the OSUCCC.

Previous articleGenzyme Jumps on the PTC124 Bandwagon Paying PTC Therapeutics $100M Upfront
Next articleFulcrum BioEnergy to Spend $120M on Solid-Waste-Fueled Ethanol Plant